Axsome commences phase 3 trial for depression drug By Investing.com

Published on 19 Mar 2024 on Investing.com

Axsome Therapeutics, Inc. (NASDAQ: NASDAQ:AXSM), a biopharmaceutical company focused on developing...

Read the rest of the article

Start tracking your investments with Statfolio

Investors in Axsome Therapeutics, Inc. (NASDAQ:AXSM) had a good week, as its shares rose 2.0% to ...

Simply Wall St. via Yahoo Finance 9 May 2024

Axsome Therapeutics, Inc. AXSM reported an adjusted loss of $1.00 per share for the first quarter...

Zacks via Yahoo Finance 8 May 2024

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript May 6, 2024 Axsome Thera...

Insider Monkey via Yahoo Finance 8 May 2024

Axsome Therapeutics (NASDAQ: NASDAQ:AXSM) reported a significant year-over-year revenue increase ...

Investing.com 7 May 2024

Axsome Therapeutics Inc (NASDAQ:AXSM), a biopharmaceutical company focused on developing novel th...

GuruFocus.com via Yahoo Finance 2 Apr 2024

In this article, we will be taking a look at the 30 countries with the lowest depression rates. I...

Insider Monkey via Yahoo Finance 26 Mar 2024

Axsome Therapeutics AXSM announced encouraging data from the phase III SYMPHONY study on its inve...

Zacks via Yahoo Finance 26 Mar 2024

In this article, we will take a look at the top 20 cloudiest cities in the U.S., Ranked. If you w...

Insider Monkey via Yahoo Finance 25 Mar 2024

Monday, Axsome Therapeutics Inc AXSM released data from the SYMPHONY Phase 3 trial of AXS-12 (reb...

Benzinga 25 Mar 2024

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a company focused on developing therapies for central...

Investing.com 25 Mar 2024